-transparent.png){kind=logo}
OBJECTIVE This study aimed to investigate the predictive value of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay for chemosensitivity test in ascites. METHODS The relationship of the in vitro sensitivity results and the clinicopathological characteristics, objective response rates (ORRs) of chemotherapy, and time to progression (TTP) were retrospectively analyzed in 120 epithelial ovarian cancer (EOC) patients. The clinical response criterion was based on the Response Evaluation Criteria in Solid Tumors (RECIST) standard. The log-rank test and Kaplan-Meier curve were used to estimate TTP. RESULTS MTT assays revealed that tumor cells from ascites of primary and type II EOC were more sensitive to paclitaxel (PTX) and carboplatin (CBDCA) than relapse (p = 0.01 and p < 0.01, respectively) and type I (p = 0.03, p = 0.02, respectively) EOC. p53 positive expression and Ki67 high expression were associated with high PTX (p = 0.01 and p < 0.01, respectively) and CBDCA (p = 0.03 and p < 0.01, respectively) sensitivity. Ki67 weak positive immunostaining was associated with topotecan (p < 0.01), gemcitabine (p < 0.01), and doxorubicin (p < 0.01) resistance. Chemosensitivity to CBDCA/PTX was associated with the ORR ofneo-adjuvant (p = 0.03) and adjuvant (p = 0.02) chemotherapy. The MTT assay results of ascites were consistent with the clinical response (p = 0.04) and TTP (p = 0.04) in patients with platinum-resistant relapse EOC tumors. CONCLUSIONS Evaluation of the chemosensitivity of ascites in EOC by MTT can aid the establishment of individualized clinical chemotherapeutic plans for platinum-resistant relapse patients.
X Xu, and
H Dai, and
Y Zhao, and
Y Wang, and
X Xu, and
Z Qian, and
X Chen
January 2012,
Acta medica Okayama,
X Xu, and
H Dai, and
Y Zhao, and
Y Wang, and
X Xu, and
Z Qian, and
X Chen
November 2010,
Zhonghua zhong liu za zhi [Chinese journal of oncology],
X Xu, and
H Dai, and
Y Zhao, and
Y Wang, and
X Xu, and
Z Qian, and
X Chen
November 2001,
Gynecologic oncology,
X Xu, and
H Dai, and
Y Zhao, and
Y Wang, and
X Xu, and
Z Qian, and
X Chen
May 2010,
Zhonghua zhong liu za zhi [Chinese journal of oncology],
X Xu, and
H Dai, and
Y Zhao, and
Y Wang, and
X Xu, and
Z Qian, and
X Chen
May 2015,
Oncology letters,
X Xu, and
H Dai, and
Y Zhao, and
Y Wang, and
X Xu, and
Z Qian, and
X Chen
August 1994,
Obstetrics and gynecology,
X Xu, and
H Dai, and
Y Zhao, and
Y Wang, and
X Xu, and
Z Qian, and
X Chen
July 1984,
Gan no rinsho. Japan journal of cancer clinics,
X Xu, and
H Dai, and
Y Zhao, and
Y Wang, and
X Xu, and
Z Qian, and
X Chen
August 1985,
The Australian & New Zealand journal of obstetrics & gynaecology,
X Xu, and
H Dai, and
Y Zhao, and
Y Wang, and
X Xu, and
Z Qian, and
X Chen
December 2009,
Archives of pharmacal research,
X Xu, and
H Dai, and
Y Zhao, and
Y Wang, and
X Xu, and
Z Qian, and
X Chen
August 1991,
American journal of obstetrics and gynecology,
